13 recruiting, 4 active not recruiting, 4 completed, 2 terminated. 4 Not applicable, 4 Phase 2, 3 Phase 1, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Recruiting 2, Completed 1, Unknown 1 |
| Phase 2 | 4 | Active not recruiting 2, Recruiting 1, Terminated 1 |
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 4 | 2 | Completed 2 |
Follow Tempus AI: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer Cancer, Solid Tumor Cancer | Recruiting | Tempus AI | 1000 | 2026-08-01 | 2026-08-10 | |
| A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis rebecsinib - Secondary AML, Myelofibrosis | Phase 1 | Recruiting | Aspera Biomedicines, Inc. | 28 | 2026-05-21 | 2026-07-20 |
| A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies None - Observational Study - Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL) | Recruiting | Tempus AI | 550 | 2026-01-27 | 2026-10-09 | |
| Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies There are no interventions in this observational study. - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Recruiting | Tempus AI | 900 | 2025-10-27 | 2026-09-03 | |
| Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator - Pulmonary Hypertension, Interstitial Lung Disease (ILD) | Not applicable | Recruiting | Tempus AI | 900 | 2025-07-23 | 2026-11-03 |
| NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) Trial Risk-Based Assessment for Cardiac Dysfunction - Atrial Fibrillation, Cardiovascular Diseases | Not applicable | Recruiting | Northwestern University | 1000 | 2024-09-16 | 2026-08-20 |
| Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform Automated alert - Aortic Valve Stenosis, Mitral Regurgitation | Not applicable | Completed | Tempus AI | 2118 | 2024-08-27 | 2026-03-06 |
| Liquid BiOpsy, Lung and Colon Cancer in AndaluciA xF Tempus assay - Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Enrolling by invitation | Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental | 500 | 2024-08-01 | 2025-05-30 | |
| A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) Head and Neck Squamous Cell Carcinoma | Recruiting | Tempus AI | 500 | 2024-08-01 | 2026-09-03 | |
| TEMPUS ARIES: A Biobank Registry Platform Study in Oncology Cancer | Recruiting | Tempus AI | 500 | 2024-06-26 | 2026-02-24 | |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression A2B694, A2B543, xT CDx with HLA-LOH Assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 474 | 2024-04-03 | 2026-06-12 |
| Umbrella Study for Analysis of Data Related to Patients With Cancer Cancer | Completed | Tempus AI | 77 | 2023-12-06 | 2026-06-29 | |
| Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer. Observation - Breast Cancer | Terminated | BioCorteX Inc | 2 | 2023-12-01 | 2024-08-02 | |
| A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression A2B530, xT-Onco with HLA-LOH Assay - Solid Tumor, Adult, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | A2 Biotherapeutics Inc. | 160 | 2023-04-28 | 2025-04-25 |
| Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease Zio Patch Monitor, Echocardiogram - Atrial Fibrillation, Structural Heart Disease | Not applicable | Unknown | Tempus AI | 1000 | 2022-09-07 | 2024-07-25 |
| Tempus Small Cell Lung Cancer Observational Study (Sculptor) Observation - Small Cell Lung Cancer | Recruiting | Tempus AI | 200 | 2022-07-13 | 2026-06-15 | |
| GEMINI-NSCLC: NSCLC Biomarker Study Observation - Non-Small Cell Lung Cancer | Recruiting | Tempus AI | 1200 | 2022-06-22 | 2026-02-05 | |
| Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays Observation - Colorectal Cancer | Recruiting | Tempus AI | 300 | 2022-06-21 | 2025-05-06 | |
| Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors Niraparib - Solid Tumor, Breast Tumor | Phase 2 | Terminated | Tempus AI | 22 | 2022-03-15 | 2025-10-29 |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing - Solid Tumor, Adult, Colorectal Cancer | Recruiting | A2 Biotherapeutics Inc. | 500 | 2021-10-29 | 2026-10-26 |
Showing 20 of 25. Sign in to see all of them.
Neoplasms (11) · Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (5) · Pancreatic Neoplasms (5) · Breast Neoplasms (4) · Colonic Neoplasms (3) · Lung Neoplasms (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Recurrence (3) · Atrial Fibrillation (2) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2) · Head and Neck Neoplasms (2) · Hematologic Neoplasms (2)
Observation (5) · Ribavirin (2) · Blood Component Removal (1) · Continuous Glucose Monitoring (1) · Echocardiography (1) · niraparib (1) · peginterferon alfa-2b (1)
United States (22) · Egypt (2) · Puerto Rico (2) · Spain (1)
Virginia Rhodes, MD (4) · Michelle Ting-Lin, MD (2) · Alaa Ismail, M.D. (1) · Amal Abdel Baky, M.D. (1) · Amany Sayed Ahmad, M.D. (1) · Apostolia M Tsimberidou (1) · Edward Ramos, PhD (1) · Eric Ng, MD (1) · Eric W Ng, MD, FAAP (1) · James Mangan, MD, PhD (1) · John Pfeifer, MD (1) · John Welch, MD, PhD (1) · Kristiyana Kaneva, MD, MS (1) · Kristiyana Kaneva, MD, MS, MBA (1) · M Jose Serrano, PhD (1)
PMID 12401529, PMID 17943989, PMID 27457512, PMID 33995588, PMID 36302890, PMID 3975954, PMID 41918932, PMID 42059855, PMID 570666